A critical biomarker of kidney disease may help predict clear cell kidney cancer—the most common form of kidney cancer—years before clinical diagnosis. Kidney-injury-molecule-1 (KIM-1) can be detected in the urine and blood and is generally present at low levels in healthy individuals. Prior research by leaders at Brigham and Women’s Hospital has shown that KIM-1 is an...
Tag: <span>kidney cancer</span>
Post
Kidney cancer’s developmental source revealed
In the first experiment of its kind, scientists have revealed the precise identity of cancer cells of the most common childhood and adult kidney cancers. Researchers from the Wellcome Sanger Institute, the University of Cambridge, University of Newcastle and their collaborators showed that the cancer cells are versions of specific healthy cells from developing or adult kidneys....
Post
First seeds of kidney cancer sown in adolescence
Insights from this study present an opportunity to develop approaches for early detection and early intervention in kidney cancer The earliest critical genetic changes that can lead to kidney cancer have been mapped by scientists. The first key genetic change occurs in childhood or adolescence, and the resulting cells follow a consistent path to progress...
Post
UT Health San Antonio researchers define mechanism that causes kidney cancer to recur
SAN ANTONIO (Oct. 23, 2017) ― New research from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) and U.S. Department of Veterans Affairs has identified the molecular mechanism that causes kidney cancer to resist drug treatment. The findings were published Oct. 19 in the journal Nature Communications. In normal cell functioning, nutrients...
Post
Targeted drug shows promise in rare advanced kidney cancer
Some patients with a form of advanced kidney cancer that carries a poor prognosis benefited from an experimental drug targeted to an abnormal genetic pathway causing cancerous growth, according to research led by a Dana-Farber Cancer Institute scientist. The drug, savolitinib, showed clinical activity in patients with metastatic papillary renal cell carcinoma (PRCC) whose tumors were driven...
Post
Immunologic changes point to potential for clinical investigation of combination immunotherapy for deadly kidney cancer
Immunologic changes observed in an early study of patients with metastatic renal cell carcinoma (MRCC) raised the possibility for a larger clinical study of combination immunotherapy, according to findings reported by researchers at The University of Texas MD Anderson Cancer Center. The results of an open-label pilot study comparing combinations of anti-PD1 (nivolumab) alone, or...
Post
‘By moving my kidney, surgeons beat the life-threatening cancer’: A new procedure did not only save Gerry’s life, but also spared her from years of dialysis
Last April, Gerry O’Neill had a CT scan which revealed a swelling on her kidney Doctors soon discovered she had cancer, and needed dialysis and a transplant Following the new op she is back to health, and wishes to resume work as a carer Kidney cancer patients may need the organ removed and can...